Compare Stocks: PMCB, AKTX, NXTC, and ALLR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$9.76 -3.0%	$9.09	$3.02 ▼ $46.00	$18.99M	1.43	85,418 shs	71,534 shs
ALLR Allarity Therapeutics	$1.03 -5.5%	$1.29	$0.77 ▼ $1.84	$16.39M	0.56	116,766 shs	43,322 shs
NXTC NextCure	$5.08 -3.8%	$6.16	$1.55 ▼ $15.74	$18.35M	1.33	108,736 shs	71,789 shs
PMCB Nuvilex	$0.44 -3.4%	$0.52	$0.33 ▼ $1.51	$4.74M	0.66	380,930 shs	399,473 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+6.55%	+8.32%	-8.10%	-78.02%
ALLR Allarity Therapeutics	0.00%	-14.88%	-25.36%	-20.77%	-36.81%
NXTC NextCure	0.00%	-16.99%	-15.75%	+208.81%	-11.65%
PMCB Nuvilex	0.00%	-4.07%	-18.36%	-42.70%	-58.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$9.76 -3.0%	$9.09	$3.02 ▼ $46.00	$18.99M	1.43	85,418 shs	71,534 shs
ALLR Allarity Therapeutics	$1.03 -5.5%	$1.29	$0.77 ▼ $1.84	$16.39M	0.56	116,766 shs	43,322 shs
NXTC NextCure	$5.08 -3.8%	$6.16	$1.55 ▼ $15.74	$18.35M	1.33	108,736 shs	71,789 shs
PMCB Nuvilex	$0.44 -3.4%	$0.52	$0.33 ▼ $1.51	$4.74M	0.66	380,930 shs	399,473 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+6.55%	+8.32%	-8.10%	-78.02%
ALLR Allarity Therapeutics	0.00%	-14.88%	-25.36%	-20.77%	-36.81%
NXTC NextCure	0.00%	-16.99%	-15.75%	+208.81%	-11.65%
PMCB Nuvilex	0.00%	-4.07%	-18.36%	-42.70%	-58.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.80	Moderate Buy	$32.33	231.28% Upside
ALLR Allarity Therapeutics	2.00	Hold	$10.25	895.15% Upside
NXTC NextCure	2.25	Hold	$19.00	274.02% Upside
PMCB Nuvilex	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PMCB, AKTX, NXTC, and ALLR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	AKTX Akari Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/2/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	NXTC NextCure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PMCB Nuvilex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
7/15/2026	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$24.75 per share	N/A
ALLR Allarity Therapeutics	$345K	47.50	N/A	N/A	$0.61 per share	1.69
NXTC NextCure	N/A	N/A	N/A	N/A	$9.97 per share	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	$2.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	12/4/2026 (Estimated)
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
NXTC NextCure	-$55.84M	-$8.70	N/A	N/A	N/A	N/A	-154.62%	-100.19%	11/4/2026 (Estimated)
PMCB Nuvilex	-$19.42M	-$2.31	N/A	N/A	N/A	N/A	-12.99%	-8.92%	12/16/2026 (Estimated)

Latest PMCB, AKTX, NXTC, and ALLR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q1 2027	PMCB Nuvilex	-$0.06	-$0.54	-$0.48	-$0.54	N/A	N/A
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/6/2026	Q2 2026	NXTC NextCure	-$1.95	-$2.80	-$0.85	-$2.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
ALLR Allarity Therapeutics	N/A	1.11	1.11
NXTC NextCure	N/A	3.47	3.47
PMCB Nuvilex	N/A	40.28	40.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
ALLR Allarity Therapeutics	11.53%
NXTC NextCure	42.65%
PMCB Nuvilex	34.24%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
ALLR Allarity Therapeutics	0.16%
NXTC NextCure	11.90%
PMCB Nuvilex	10.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	5	1.95 million	1.32 million	Not Optionable
ALLR Allarity Therapeutics	8	15.91 million	15.89 million	Not Optionable
NXTC NextCure	40	3.61 million	3.18 million	No Data
PMCB Nuvilex	2	10.74 million	9.56 million	Optionable

PMCB, AKTX, NXTC, and ALLR Headlines

Recent News About These Companies

Insider Buying: Nuvilex (NASDAQ:PMCB) Director Acquires 20,000 Shares of Stock

January 8, 2026 | insidertrades.com

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

September 2, 2025 | businesswire.com

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

August 20, 2025 | businesswire.com

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

August 18, 2025 | businesswire.com

MyMD Pharmaceuticals Secures Strategic Investments

May 21, 2024 | businesswire.com

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

May 21, 2024 | businesswire.com

PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024

December 18, 2023 | msn.com

Companies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In Growth

December 15, 2023 | finance.yahoo.com

PharmaCyte Biotech Inc PMCB

December 5, 2023 | morningstar.comM

With biotech in a slump, the industry’s job market is upside down

November 28, 2023 | statnews.comS

The return of biotech’s “bump factor” amid an economic downturn

November 24, 2023 | statnews.comS

PharmaCyte Biotech: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And Exhibits

November 18, 2023 | cbonds.comC

PharmaCyte Biotech Invests In Femasys - Quick Facts

November 15, 2023 | markets.businessinsider.com

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

November 15, 2023 | finance.yahoo.com

Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs

October 23, 2023 | statnews.comS

PharmaCyte completes tender offer to purchase shares

June 15, 2023 | msn.com

PharmaCyte Biotech Announces Final Results of Tender Offer

June 15, 2023 | finance.yahoo.com

Los Angeles Biotech News

June 14, 2023 | bizjournals.com

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

May 11, 2023 | finance.yahoo.com

Biotech ETFs’ Performance Deserves A Look

April 21, 2023 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, AKTX, NXTC, and ALLR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$9.76 -0.30 (-2.98%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$10.10 +0.35 (+3.53%)

As of 09/25/2026 07:12 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Allarity Therapeutics NASDAQ:ALLR

$1.03 -0.06 (-5.50%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$1.05 +0.02 (+1.84%)

As of 09/25/2026 07:02 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

NextCure NASDAQ:NXTC

$5.08 -0.20 (-3.79%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$5.08 0.00 (-0.10%)

As of 09/25/2026 07:30 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Nuvilex NASDAQ:PMCB

$0.44 -0.02 (-3.37%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$0.44 +0.00 (+0.23%)

As of 09/25/2026 07:53 PM Eastern

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMCB, AKTX, NXTC, and ALLR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMCB, AKTX, NXTC, and ALLR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMCB, AKTX, NXTC, and ALLR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, AKTX, NXTC, and ALLR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Allarity Therapeutics NASDAQ:ALLR

NextCure NASDAQ:NXTC

Nuvilex NASDAQ:PMCB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PMCB, AKTX, NXTC, and ALLR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PMCB, AKTX, NXTC, and ALLR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PMCB, AKTX, NXTC, and ALLR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, AKTX, NXTC, and ALLR Company Descriptions

Akari Therapeutics NASDAQ:AKTX

Allarity Therapeutics NASDAQ:ALLR

NextCure NASDAQ:NXTC

Nuvilex NASDAQ:PMCB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools